Skip to content
No results
  • About Us
  • Contact Us
  • Disclaimer
  • Events and Conferences
  • Home
  • Organizer Dashboard
  • Privacy Policy
  • Submit Organizer Form
  • Submit Venue Form
  • Subscribe
  • Terms and Conditions
  • Venue Dashboard
  • About Us
  • Contact Us
The Pharma Data

  • News
  • Press Releases
  • Research
  • Business
  • Regulatory
  • Events and Conferences
The Pharma Data
  • News

Intellia Reports Positive 3-Year Phase 1 Data for Lonvo-z in Hereditary Angioedema

  • The Pharma Data
  • June 16, 2025

Intellia Therapeutics Reports Positive 3-Year Phase 1 Data for Lonvo-z in Hereditary Angioedema — Highlights Durable Benefit and Safety Intellia Therapeutics, a leading clinical-stage genome-editing biotechnology company, today presented updated…

Read MoreIntellia Reports Positive 3-Year Phase 1 Data for Lonvo-z in Hereditary Angioedema
  • News

Sarepta Strengthens ELEVIDYS Safety Measures for Non-Ambulatory Duchenne Patients

  • The Pharma Data
  • June 16, 2025

Sarepta Takes Action to Strengthen ELEVIDYS Safety Measures in Non-Ambulatory Duchenne Patients Sarepta Therapeutic a leading innovator in precision genetic medicine for rare disorders, today provided a significant safety update…

Read MoreSarepta Strengthens ELEVIDYS Safety Measures for Non-Ambulatory Duchenne Patients
  • News

QIAGEN and Incyte Partner on Companion Dx for Mutant CALR MPNs

  • The Pharma Data
  • June 16, 2025

QIAGEN and Incyte Forge Global Collaboration to Develop Companion Diagnostic Panel for Patients With Mutant CALR-Positive Myeloproliferative Neoplasms QIAGEN N.V. and Incyte today announced a significant new collaboration aimed at…

Read MoreQIAGEN and Incyte Partner on Companion Dx for Mutant CALR MPNs
  • News

Genmab: Epcoritamab Combo Shows High Response in Transplant-Eligible R/R DLBCL

  • The Pharma Data
  • June 16, 2025

Genmab Presents Positive Epcoritamab Combination Data in Relapsed or Refractory DLBCL Eligible for Autologous Stem Cell Transplantation Genmab A/S today shared new and highly promising data from its Phase 1b/2…

Read MoreGenmab: Epcoritamab Combo Shows High Response in Transplant-Eligible R/R DLBCL
  • News

EAACI: Dupixent Supersedes Xolair in CRS w/ Nasal Polyps and Asthma Phase 4 Head-to-Head Study

  • The Pharma Data
  • June 16, 2025

Sanofi and Regeneron’s Dupixent Shows Superiority over Xolair in First-Ever Head-to-Head Phase 4 Study in Patients with Severe Chronic Rhinosinusitis with Nasal Polyps and Co-existing Asthma Sanofi and Regeneron Pharmaceuticals,…

Read MoreEAACI: Dupixent Supersedes Xolair in CRS w/ Nasal Polyps and Asthma Phase 4 Head-to-Head Study
  • News

Roche shares Elevidys safety update in non-ambulatory Duchenne muscular dystrophy patients

  • The Pharma Data
  • June 16, 2025

Roche Suspends Elevidys Dosing in Non-Ambulatory DMD Patients Amid Safety Concerns Roche today announced a significant update to its dosing guidelines for Elevidys™ (delandistrogene moxeparvovec), following a careful reassessment of…

Read MoreRoche shares Elevidys safety update in non-ambulatory Duchenne muscular dystrophy patients
  • News

TALVEY + TECVAYLI Provide Durable Responses in Extramedullary Multiple Myeloma

  • The Pharma Data
  • June 16, 2025

Johnson & Johnson’s RedirecTT-1 Study Shows Durable Responses in Heavily Pretreated Multiple Myeloma Patients with Extramedullary Disease Johnson & Johnson today presented new and promising data from its Phase 2…

Read MoreTALVEY + TECVAYLI Provide Durable Responses in Extramedullary Multiple Myeloma
  • News

Elanco’s Zenrelia Wins Positive CVMP Opinion

  • The Pharma Data
  • June 14, 2025

Elanco’s Zenrelia (ilunocitinib) Wins Positive CVMP Opinion, Paving the Way for EU Approval and Market Release Elanco Animal Health Incorporated (NYSE: ELAN) today announces a significant milestone in its ongoing…

Read MoreElanco’s Zenrelia Wins Positive CVMP Opinion
  • News

mRNA Tech Transfer Phase 2.0 Discussed at G20 Summit

  • The Pharma Data
  • June 14, 2025

mRNA Technology Transfer Programme Moves Into Phase 2.0, Boosting Sustainable Local Vaccine Manufacturing and Global Health Security In parallel with the G20 Health Working Group meeting, global health leaders and…

Read MoremRNA Tech Transfer Phase 2.0 Discussed at G20 Summit
  • News

Astellas, Mitsubishi Research Institute Team Up to Support Japanese Pharma Startups

  • The Pharma Data
  • June 14, 2025

Mitsubishi Research Institute and Astellas Forge Collaborative Initiative to Support Japanese Drug Discovery Startups and Boost Global Innovation Mitsubishi Research Institute, Inc. (MRI) and Astellas Pharma Inc. (Astellas) today announced…

Read MoreAstellas, Mitsubishi Research Institute Team Up to Support Japanese Pharma Startups
  • News

Amgen & Barry Sanders Spotlight Bad Cholesterol Risks in Documentary

  • The Pharma Data
  • June 14, 2025

Amgen and Barry Sanders Raise Awareness About “Bad Cholesterol” in Documentary Highlighting Cardiovascular Disease Crisis in America Amgen today announced the launch of The Making of a Heart Attack, a…

Read MoreAmgen & Barry Sanders Spotlight Bad Cholesterol Risks in Documentary
  • NewsResearch

FDA Approves KEYTRUDA for Neoadjuvant and Adjuvant Treatment of PD-L1+ Resectable Head & Neck Cancer

  • The Pharma Data
  • June 14, 2025

FDA Approves KEYTRUDA® (Pembrolizumab) for Perioperative Treatment of Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma Merck known as MSD outside the United States and Canada, recently announced that…

Read MoreFDA Approves KEYTRUDA for Neoadjuvant and Adjuvant Treatment of PD-L1+ Resectable Head & Neck Cancer
Next

About

The Pharma Data is an Information-Centric Website focused mainly on the Pharmaceutical Industry Online It is a B2B Platform mainly focused on the latest Pharmaceutical News, Press releases, Industry-related updates, Events, and Conferences. With The Pharma Data, you can get all the information that happening in the Pharmaceutical industry.

Advertise With Us: [email protected]

Latest Posts

  • Intellia Reports Positive 3-Year Phase 1 Data for Lonvo-z in Hereditary Angioedema
  • Sarepta Strengthens ELEVIDYS Safety Measures for Non-Ambulatory Duchenne Patients
  • QIAGEN and Incyte Partner on Companion Dx for Mutant CALR MPNs
  • About Us
  • Disclaimer
  • Privacy Policy
  • Terms and Conditions
  • Contact Us

Copyright © 2025 | The Pharma Data | All Rights Reserved.